We look forward to supporting innovation in the life science industry by continuing to deliver effective risk transfer ...

The JADE study will be evaluating BI 1584862, an investigational oral compound that targets inflammation and preserves ...

researchers and participants throughout all phases of clinical research and is tailored to meet the regulatory requirements of more than 100 territories, ensuring smooth and compliant trial ...

Safety, Tolerability, and Preliminary Efficacy of JBZ-001 in Patients with Advanced Solid Tumors and Non-Hodgkin Lymphoma CRANBERRY TOWNSHIP, PENNSYLVANIA / ACCESS Newswire / May 9, 2025 / Jabez Biosc ...

A potential game changer in the treatment of retinal disease, the novel dual-target drug shows encouraging results.

Inhibition of GSK-3β may inhibit tumor growth and improve survival through several complimentary mechanisms that include enhancement of chemotherapy activity, activation of innate anti-tumor immunity, ...

researchers and participants throughout all phases of clinical research and is tailored to meet the regulatory requirements of more than 100 territories, ensuring smooth and compliant trial operations ...

Cambridge, Massachusetts Saturday, May 10, 2025, 18:00 Hrs [IST] ...

Avance Clinical, the award-winning, global CRO for biotechs, is proud to announce its sponsorship of the Citeline Awards 2025 ...